• Investment date: July 18, 2019
  • Initial investment stage: Series B
  • Current company stage: Series B
  • Market category: Active, Healthtech, via Syndicates

Peter Quinzio


Notable is a mission-driven company transforming the way cancer is treated through a translational drug discovery platform focused on identifying therapeutic options for cancer patients.

Clinical lab service: We help doctors identify personalized combinations of FDA-approved treatments for their cancer patients. Focusing on individual patients + existing treatments, we’re discovering new uses of drugs and defining mechanisms underlying cancer progression and drug resistance. Using robotic + modern data science, we’re building a scalable, iterative model that will turn individual treatment selection into a data problem.

R&D platform: The clinical lab service acts as a funnel to acquire primary patient samples for biopharma partnerships. Using our automated, multi-parametric drug screening research platform, collaborators can assay the biological impact of compounds on primary cells in a physiologically relevant environment. This platform helps our partners stratify patients, de-risking drug development and increasing their probability of success.

July 16, 2019: Notable Labs Lands $40m to Expand AI-Based Cancer Treatment Tech